DCAA Executive Compensation Calculation Rejected (Again)
Client Alert | less than 1 min read | 06.21.12
In Metron, Inc., decided on June 4 by the ASBCA, DCAA's flawed methodology for assessing the reasonableness of executive compensation paid by government contractors was rejected for the second time this year by the Board. The board found that Metron appropriately based its compensation decisions on data in a single survey that was most relevant to Metron's business, found that other survey data that DCAA relied on was not relevant to Metron's compensation costs, and rejected all of the "adjustments" that DCAA had made to the relevant survey data because the adjustments were based on speculation and assumptions that were not supported by factual evidence.
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief
